Read by QxMD icon Read


Anna Mosikian, Antonina Dolgorukova, Alsu Zalevskaya
AIM: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. MATERIALS & METHODS: We have collected the current data on correlation between SUs pharmacodynamics and CYP2C9 polymorphisms. We have evaluated the frequency of CYP2C9 polymorphisms in Russia by reviewing the literature published from 2004 to 2015 on Russian CYP2C9. RESULTS: The genotype *1/*1, which confers risk for treatment failure, has a higher frequency (81...
November 25, 2016: Pharmacogenomics
Suvi Koskinen, Olli Kampman, Anssi Solismaa, Leo-Pekka Lyytikäinen, Niko Seppälä, Merja Viikki, Mari Hämäläinen, Eeva Moilanen, Nina Mononen, Terho Lehtimäki, Esa Leinonen
AIM: To investigate INSIG2's association with obesity, weight change and serum lipid profile during clozapine treatment. MATERIALS & METHODS: Subjects with schizophrenia (n = 190) were genotyped, identifying seven SNPs. Genetic risk scores (GRSs) were calculated to adiponectin, high-density lipoprotein cholesterol, triglycerides and weight gain. RESULTS: In the model for weight gain, SNPs rs12151787, rs17047733 and rs10490626 were selected...
November 25, 2016: Pharmacogenomics
Mateusz Kurzawski, Damian Malinowski, Natalia Szarmach, Anna Nowak, Aleksandra Goryniak, Andrzej Pawlik, Marek Droździk
AIM: The study was aimed at investigation of several gene variants of folate pathway enzymes for their potential association with methotrexate (MTX) treatment response in patients with rheumatoid arthritis. PATIENTS & METHODS: Four hundred and twenty two Caucasian patients were classified as good or poor responders, and subsequently genotyped for common SNPs in DHFR, FPGS and ATIC genes. RESULTS: No significant differences were observed in case of DHFR and FGPS SNPs...
November 25, 2016: Pharmacogenomics
Misbahuddin M Rafeeq, Farida Ahmad, Syed Z Rahman, Sheelu S Siddiqi, Shazi Shakeel
AIM: Statins treat dyslipidemia associated with metabolic syndrome. Genetic factors contribute to variable response. Sterol regulatory element-binding factors cleavage-activating protein (SCAP) pathway regulates lipid homeostasis, so effect of SNP in SCAP gene on rosuvastatin response was studied. MATERIALS & METHODS: Metabolic syndrome patients with low-density lipoprotein-cholesterol ≥130 mg/dl, were prescribed rosuvastatin 5 mg for 3 months. Lipids were measured initially and finally, and genotyping done...
November 25, 2016: Pharmacogenomics
Tristan M Sissung, John Deeken, Crystal R Leibrand, Douglas K Price, Sheryl Ehrlich, Seth M Steinberg, David J Liewehr, William Dahut, William D Figg
AIM: Metabolism and transport play major roles in life-long exposure to endogenous and exogenous carcinogens. We therefore explored associations between polymorphisms in absorption, distribution, metabolism and elimination genes and the risk and prognosis of castration-resistant prostate cancer (CRPC). MATERIALS & METHODS: A total of 634 genotypes were tested in 74 patients using the Affymetrix DMETv1.0 platform. RESULTS: No relation to risk was found...
November 24, 2016: Pharmacogenomics
Xiaoyu Hu, Ellie H Jhun, Yingwei Yao, Ying He, Robert E Molokie, Diana J Wilkie, Zaijie J Wang
AIM: Pain is prevalent in sickle cell disease (SCD) patients who display great heterogeneity in pain severity and frequency. Hypothesizing that inflammatory factors are involved in the pathogenesis of SCD pain, we focused on the IL1A C/T polymorphism rs1800587 that is an SNP located in a cis-transcriptional regulatory region. METHODS: We genotyped IL1A rs1800587 and performed association studies with phenotype data obtained by a multidimensional pain assessment tool using the PAINReportIt(®) Questionnaire...
November 24, 2016: Pharmacogenomics
Claudia M Hattinger, Serena Vella, Elisa Tavanti, Marilù Fanelli, Piero Picci, Massimo Serra
Second-line treatment of high-grade osteosarcoma (HGOS) patients is based on different approaches and chemotherapy protocols, which are not yet standardized. Although several drugs have been used in HGOS second-line protocols, none of them has provided fully satisfactory results and the role of rescue chemotherapy is not well defined yet. This article focuses on the drugs that have most frequently been used for second-line treatment of HGOS, highlighting the present knowledge on their mechanisms of action and resistance and on gene polymorphisms with possible impact on treatment sensitivity or toxicity...
November 24, 2016: Pharmacogenomics
Marzia Del Re, Eleonora Rofi, Valentina Citi, Leonardo Fidilio, Romano Danesi
No abstract text is available yet for this article.
November 24, 2016: Pharmacogenomics
Kavisha Singh, Bruce Peyser, Gloria Trujillo, Nicholas Milazzo, Dillon Savard, Susanne B Haga, Michael Musty, Deepak Voora
No abstract text is available yet for this article.
November 3, 2016: Pharmacogenomics
Sylvia Chen, Natalia Sutiman, Balram Chowbay
The use of imatinib in the treatment of BCR-ABL-positive chronic myeloid leukemia and gastrointestinal stromal tumors has significantly improved survival outcomes in patients afflicted by these malignancies. However, a substantial proportion of imatinib-treated patients still experience treatment failure. Suboptimal concentrations of imatinib have been postulated to contribute at least partially to the development of resistance against imatinib. Indeed, variations in the genes encoding drug transporters have been reported to markedly influence imatinib disposition and treatment outcomes in various populations...
November 2, 2016: Pharmacogenomics
Keqin Gregg, Wenjing Guo, Robert Rhodes, Ashrita Simhadri, Archana Subramanya, Paul Samilpa, Lyndsey Langley, Kyle Ames, Matt McCarty
AIM: This study investigated the possible cause of false positive detection of CYP2D6 gene duplication (CYP2D6XN) using the standard TaqMan-based real-time PCR assay from Thermo Fisher Scientific. METHODS: Used samples of two copy carriers as control to evaluate the effect of sample storage condition and the reference genes with respect to test accuracy. RESULTS: The standard test from Thermo Fisher Scientific produced false positive results of the CYP2D6XN detection when samples were exposed to high temperature and high humidity...
November 1, 2016: Pharmacogenomics
Katy Sánchez-Pozos, Carolina Rivera-Santiago, María Helena García-Rodríguez, María Guadalupe Ortiz-López, Barbara Itzel Peña-Espinoza, María de Los Ángeles Granados-Silvestre, Adrian Llerena, Marta Menjívar
AIM: CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphisms in CYP2C9 gene and pharmacological implications in Mexican indigenous populations. Thus, frequencies of CYP2C9*2 and CYP2C9*3 alleles were evaluated in indigenous groups located in northwest (Cora), center (Mazahua and Teenek), south (Chatino and Mixteco) and southeast (Chontal and Maya) regions Mexico. MATERIALS & METHODS: Allelic discrimination was performed by real-time PCR...
October 28, 2016: Pharmacogenomics
Jason D Roberts, Gregory M Marcus
Previously confined to the management of rare inherited arrhythmia syndromes, a role for genetics within cardiac electrophysiology has begun to emerge for more common arrhythmias, including atrial fibrillation (AF). Catheter ablation for AF is an invasive procedure effective for restoring normal rhythm, however, fails in up to 40% of those undergoing their first procedure and carries a risk for serious adverse events. Recent studies have suggested that a common genetic variant within chromosome 4q25 may be a powerful predictor of procedural success, highlighting the potential of an 'ablatogenomic' strategy...
October 28, 2016: Pharmacogenomics
Monir Sadat Haerian, Batoul Sadat Haerian, Saadat Molanaei, Farid Kosari, Shahram Sabeti, Farahnaz Bidari-Zerehpoosh, Ebrahim Abdolali, Mohammad Reza Zali
: Several studies have investigated whether MTHFR rs1801133 polymorphism contributes to risk of colorectal cancer (CRC), however the results are inconclusive. AIM: The purpose of this study was to investigate this hypothesis in a case-control study and meta-analysis in Iranian population. MATERIALS & METHODS: This polymorphism was genotyped in the 2421 subjects (46% CRC patients) from Tehran. Meta-analysis was performed for determining the risk effect size of this polymorphism on CRC...
October 28, 2016: Pharmacogenomics
Martha Sosa-Macías, Enrique Teran, William Waters, Martha M Fors, Catalina Altamirano, Helgi Jung-Cook, Carlos Galaviz-Hernández, Marisol López-López, Diadelis Remírez, Graciela E Moya, Francisco Hernández, Humberto Fariñas, Ronald Ramírez, Carolina Céspedes-Garro, Eduardo Tarazona-Santos, Adrián LLerena
Congress of Pharmacogenetics and Personalized Medicine. Ethnicity, clinical implementation and regulatory environment (MESTIFAR 2016 Quito). Quito, Ecuador, 19-21 May 2016. The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) was created in 2006 with the main aim of promoting personalized medicine and collaborative pharmacogenetics research in Spanish- and Portuguese-speaking countries in America and the Iberian Peninsula. The final goal of this initiative was the inclusion of Latin American populations that may benefit from the implementation of personalized medicine in drug therapy...
October 28, 2016: Pharmacogenomics
Cindy T Pau, Kai I Cheang, Bhavi P Modi, Thushiga Kasippillai, Candace C Keefe, Maria Shulleeta, William S Evans, Lubna Pal, Jerome F Strauss, John E Nestler, Corrine K Welt
AIMS: Variants in genes encoding metformin transport proteins and the ATM gene are associated with metformin response. We hypothesized that these gene variants contribute to variable metformin treatment response in polycystic ovary syndrome. MATERIALS & METHODS: The discovery cohort (n = 38) was studied in an open-label study. Results were replicated in two additional cohorts (n = 26 and n = 131). Response was assessed after 3-6 months of treatment with metformin extended-release 1500-2000 mg/day...
October 28, 2016: Pharmacogenomics
Xiaoman Liu, Jane Beith, Siew-Kee Low, Alan V Boddy
No abstract text is available yet for this article.
October 28, 2016: Pharmacogenomics
Ingrid Fricke-Galindo, Alberto Ortega-Vázquez, Nancy Monroy-Jaramillo, Pedro Dorado, Helgi Jung-Cook, Eva Peñas-Lledó, Adrián LLerena, Marisol López-López
AIM: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy in Mexican-Mestizo (MM) healthy volunteers, and to evaluate whether these are different from those reported for other populations. SUBJECTS & METHODS: Thirty-nine variants of CYP3A5, EPHX1, NR1I2, HNF4A, UGT1A1, UGT2B7, ABCC2, RALBP1, SCN1A, SCN2A and GABRA1 were genotyped in 300 MM healthy volunteers. RESULTS: All studied alleles were presented in MM, except for seven UGT1A1 variants (*6-8, 14, 15, 27 and 29)...
October 28, 2016: Pharmacogenomics
George P Patrinos, Theodora Katsila
The Pharmacogenomics and Personalized Medicine group belongs to the Laboratory of Molecular Biology and Immunology, Department of Pharmacy and is active since 2009 mainly in the field of pharmacogenomics and personalized medicine. Herein, we describe the research interests, collaborations and accomplishments of the Pharmacogenomics and Personalized Medicine group together with the teaching activities of the group that greatly enhance the pharmacogenomics knowledge of graduate/postgraduate students and healthcare professionals...
October 28, 2016: Pharmacogenomics
Louise M Andrews, Brenda Cm De Winter, Teun Van Gelder, Dennis A Hesselink
No abstract text is available yet for this article.
October 28, 2016: Pharmacogenomics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"